Literature DB >> 32520399

Artesunate interacts with the vitamin D receptor to reverse sepsis-induced immunosuppression in a mouse model via enhancing autophagy.

Shenglan Shang1,2, Jiaqi Wu1, Xiaoli Li1, Xin Liu1, Pan Li1,3, Chunli Zheng4, Yonghua Wang4, Songqing Liu2, Jiang Zheng1, Hong Zhou1,3,5.   

Abstract

BACKGROUND AND
PURPOSE: Immunosuppression is the predominant cause of mortality for sepsis because of failure to eradicate pathogens. No effective and specific drugs capable of reversing immunosuppression are clinically available. Evidences implicate the involvement of the vitamin D receptor (NR1I1) in sepsis-induced immunosuppression. The anti-malarial artesunate was investigated to determine action on sepsis-induced immunosuppression. EXPERIMENTAL APPROACH: The effect of artesunate on sepsis-induced immunosuppression was investigated in mice and human and mice cell lines. Bioinformatics predicted vitamin D receptor as a candidate target for artesunate, which was then identified using PCR and immunoblotting. Vdr, Atg16l1 and NF-κB p65 were modified to investigate artesunate 's effect on pro-inflammatory cytokines release, bacterial clearance and autophagy activities in sepsis-induced immunosuppression. KEY
RESULTS: Artesunate significantly reduced the mortality of caecal ligation and puncture (CLP)-induced sepsis immunosuppression mice challenged with Pseudomonas aeruginosa and enhanced pro-inflammatory cytokine release and bacterial clearance to reverse sepsis-induced immunosuppression in vivo and in vitro. Mechanistically, artesunate interacted with vitamin D receptor, inhibiting its nuclear translocation, which influenced ATG16L1 transcription and subsequent autophagy activity. Artesunate inhibited the physical interaction between vitamin D receptor and NF-κB p65 in LPS-tolerant macrophages and then promoted the nuclear translocation of NF-κB p65, which activated the transcription of NF-κB p65 target genes such as pro-inflammatory cytokines. CONCLUSION AND IMPLICATIONS: Our findings provide evidence that artesunate interacted with vitamin D receptor to reverse sepsis-induced immunosuppression in an autophagy and NF-κB-dependent manner, highlighting a novel approach for sepsis treatment and drug repurposing of artesunate has a bidirectional immunomodulator.
© 2020 The British Pharmacological Society.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32520399      PMCID: PMC7443466          DOI: 10.1111/bph.15158

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  61 in total

Review 1.  The two NF-kappaB activation pathways and their role in innate and adaptive immunity.

Authors:  Giuseppina Bonizzi; Michael Karin
Journal:  Trends Immunol       Date:  2004-06       Impact factor: 16.687

2.  Structure of the full human RXR/VDR nuclear receptor heterodimer complex with its DR3 target DNA.

Authors:  Igor Orlov; Natacha Rochel; Dino Moras; Bruno P Klaholz
Journal:  EMBO J       Date:  2011-12-16       Impact factor: 11.598

3.  Artesunate interacts with the vitamin D receptor to reverse sepsis-induced immunosuppression in a mouse model via enhancing autophagy.

Authors:  Shenglan Shang; Jiaqi Wu; Xiaoli Li; Xin Liu; Pan Li; Chunli Zheng; Yonghua Wang; Songqing Liu; Jiang Zheng; Hong Zhou
Journal:  Br J Pharmacol       Date:  2020-07-06       Impact factor: 8.739

4.  The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3).

Authors:  Mervyn Singer; Clifford S Deutschman; Christopher Warren Seymour; Manu Shankar-Hari; Djillali Annane; Michael Bauer; Rinaldo Bellomo; Gordon R Bernard; Jean-Daniel Chiche; Craig M Coopersmith; Richard S Hotchkiss; Mitchell M Levy; John C Marshall; Greg S Martin; Steven M Opal; Gordon D Rubenfeld; Tom van der Poll; Jean-Louis Vincent; Derek C Angus
Journal:  JAMA       Date:  2016-02-23       Impact factor: 56.272

5.  Goals and practicalities of immunoblotting and immunohistochemistry: A guide for submission to the British Journal of Pharmacology.

Authors:  Steve P H Alexander; Richard E Roberts; Brad R S Broughton; Christopher G Sobey; Christopher H George; S Clare Stanford; Giuseppe Cirino; James R Docherty; Mark A Giembycz; Daniel Hoyer; Paul A Insel; Angelo A Izzo; Yong Ji; David J MacEwan; Jonathan Mangum; Sue Wonnacott; Amrita Ahluwalia
Journal:  Br J Pharmacol       Date:  2018-02       Impact factor: 8.739

Review 6.  Vitamin D and outcomes in adult critically ill patients. A systematic review and meta-analysis of randomized trials.

Authors:  Alessandro Putzu; Alessandro Belletti; Tiziano Cassina; Sara Clivio; Giacomo Monti; Alberto Zangrillo; Giovanni Landoni
Journal:  J Crit Care       Date:  2016-11-09       Impact factor: 3.425

Review 7.  Single versus combined immunoregulatory approach using PD-1 and CTLA-4 modulators in controlling sepsis.

Authors:  Courtney P Rudick; David L Cornell; Devendra K Agrawal
Journal:  Expert Rev Clin Immunol       Date:  2017-07-28       Impact factor: 4.473

8.  Artesunate protects sepsis model mice challenged with Staphylococcus aureus by decreasing TNF-alpha release via inhibition TLR2 and Nod2 mRNA expressions and transcription factor NF-kappaB activation.

Authors:  Bin Li; Jun Li; Xichun Pan; Guofu Ding; Hongwei Cao; Weiwei Jiang; Jiang Zheng; Hong Zhou
Journal:  Int Immunopharmacol       Date:  2009-12-11       Impact factor: 4.932

Review 9.  Immunosuppression in sepsis: a novel understanding of the disorder and a new therapeutic approach.

Authors:  Richard S Hotchkiss; Guillaume Monneret; Didier Payen
Journal:  Lancet Infect Dis       Date:  2013-03       Impact factor: 25.071

10.  Intestinal epithelial vitamin D receptor deletion leads to defective autophagy in colitis.

Authors:  Shaoping Wu; Yong-Guo Zhang; Rong Lu; Yinglin Xia; David Zhou; Elaine O Petrof; Erika C Claud; Di Chen; Eugene B Chang; Geert Carmeliet; Jun Sun
Journal:  Gut       Date:  2014-07-30       Impact factor: 23.059

View more
  7 in total

1.  Artesunate interacts with the vitamin D receptor to reverse sepsis-induced immunosuppression in a mouse model via enhancing autophagy.

Authors:  Shenglan Shang; Jiaqi Wu; Xiaoli Li; Xin Liu; Pan Li; Chunli Zheng; Yonghua Wang; Songqing Liu; Jiang Zheng; Hong Zhou
Journal:  Br J Pharmacol       Date:  2020-07-06       Impact factor: 8.739

2.  Dynamic Monitoring of Immunoinflammatory Response Identifies Immunoswitching Characteristics of Severe Acute Pancreatitis in Rats.

Authors:  Qian Zhuang; Liqiang Huang; Yue Zeng; Xu Wu; Gan Qiao; Minghua Liu; Lulu Wang; Yejiang Zhou; Yuxia Xiong
Journal:  Front Immunol       Date:  2022-05-19       Impact factor: 8.786

3.  Vitamin D Receptor Is a Sepsis-Susceptibility Gene in Chinese Children.

Authors:  Danni He; Xiuxiu Lu; Wei Li; Yuanyuan Wang; Ning Li; Yuanmei Chen; Lipeng Zhang; Wenquan Niu; Qi Zhang
Journal:  Med Sci Monit       Date:  2021-10-24

Review 4.  New Insights into Artesunate as a Pleiotropic Regulator of Innate and Adaptive Immune Cells.

Authors:  Lixian Lin; Zengqi Tang; Zhenrui Shi; Qing Guo; Hui Xiong
Journal:  J Immunol Res       Date:  2022-02-07       Impact factor: 4.818

5.  The Anti-Sepsis Effect of Isocorydine Screened from Guizhou Ethnic Medicine is Closely Related to Upregulation of Vitamin D Receptor Expression and Inhibition of NFκB p65 Translocation into the Nucleus.

Authors:  Jing Luo; Nuoyan Wang; Ling Hua; Fei Deng; Dan Liu; Jun Zhou; Yue Yuan; Fumin Ouyang; Xuemin Chen; Shujuan Long; Yasi Huang; Zhanxing Hu; Hong Zhou
Journal:  J Inflamm Res       Date:  2022-10-03

6.  Artesunate protects immunosuppression mice induced by glucocorticoids via enhancing pro-inflammatory cytokines release and bacterial clearance.

Authors:  Yan Wang; Mengling Liao; Yu Zhang; Fei Deng; Jing Luo; Nuoyan Wang; Min Liu; Lin Ao; Qimei Fang; Qingchun Wang; Hong Zhou
Journal:  Eur J Pharmacol       Date:  2020-10-10       Impact factor: 4.432

Review 7.  Recent Advances in the Therapeutic Efficacy of Artesunate.

Authors:  Ngonidzashe Ruwizhi; Rejoice Bethusile Maseko; Blessing Atim Aderibigbe
Journal:  Pharmaceutics       Date:  2022-02-25       Impact factor: 6.321

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.